Citations

Clear

1526 citation(s) found for "Sun, Yu".

0266 Sleep Spindle-Duration: A Potential Biomarker for Neurodegenerative Disorder Phenotyping
Levendowski, Daniel J. , Walsh, Christine M., Boeve, Bradley, Salat, David H. , Hamilton, Joanne M., Lee‐Iannotti, Joyce , Westbrook, Philip, Mazeika, Gandis, Walsh, Christine M. , Tsuang, Debby W. , Shprecher, David , Westbrook, Philip R., Berka, Chris , Mazeika, Gandis, Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A120-A120

10.1093/sleep/zsac079.264 Get It

Abstract Introduction Decreased sleep spindle oscillations were previously associated with cognitive decline in older adults, increased tau levels, and phenoconversion to dementia in patients with Parkinson disease (PD). We analyzed quantitative sleep spindle measures to determine if this biomarker was associated with particular neurodegenerative disorder syndromes. Methods Sleep spindle oscillations ascertained in patients broadly characterized as presumed Parkinsonian-spectrum disorders (PSD), which included the subtypes dementia with Lewy Bodies/Parkinson Disease Dementia (DLB/PDD, n=16), PD (n=16), isolated REM sleep behavior disorder (iRBD, n=19), and progressive supranuclear palsy (PSP, n=13), were compared with non-PSD subtypes Alzheimer Disease dementia (AD, n=22), mild cognitive impairment (MCI, n=35), and normal cognition (NC, n=61). Sleep Profiler studies were conducted in all participants. The automated spindle detection algorithms recognized temporal excursions in the alpha (8-12 Hz) and sigma (12-16 Hz) power of 250 milliseconds or greater, with spindle duration being the sum of all spindle elapsed times. Night-to-night variability was assessed in PSP=13, PD=16, DLB/PDD=12, AD=17, MCI=25, and NC=53. Statistical analyses included intraclass correlations (ICC) and Bland-Altman plots for two-night data, and Mann-Whitney U-tests and multiple logistic regression applied to sleep-time weight-averaged spindle-durations. Results The night-to-night spindle-duration ICC was 0.95 (P<0.0001), with a Bland-Altman bias of 0.05+/-2.83 minutes. Spindle-duration was independently associated with PSD versus non-PSD groups (P=0.017, OR 1.08, 95%-CI 1.01-1.15), but not significantly associated with age (P=0.12, OR 1.03, 95%-CI 0.99-1.07) or sex (P=0.54). When stratified by subtype, age was associated with spindle-duration when NC were compared to AD and MCI (P=0.0003, OR 1.10, 95%-CI 1.04-1.16) and when iRBD were compared to DLB/PDD, PD and PSP (P<0.05, OR 1.00, 95%-CI 0.89-1.13)Spindle-durations were reduced in PSP (0.9+/-2.1) and DLB/PDD (2.0+/-5.1) when individually compared to AD (3.2+/-7.1), iRBD (3.3+/-3.4), PD (5.3+/-6.6), MCI (5.3+/-9.7), and NC (8.0+/-11.1) subtypes (all P<0.05). AD patients also exhibited lower spindle-durations than NC (P=0.03). Conclusion Auto-detected sleep spindle-durations exhibited excellent night-to-night reliability in both NC and patients with neurologic disorders. Decreased sleep spindle-duration was independently associated with PSP and DLB/PDD, and in AD. Reduced sleep spindle duration may be a distinct sleep biomarker for those disorders likely indicating thalamocortical dysfunction. Support (If Any) NIA grants: R44AG050326, R44AG054256, P30AG62677 and R34AG56639.
0267 The Influence of Antidepressants on Non-REM Hypertonia
Levendowski, Daniel J. , Boeve, Bradley, Walsh, Christine M., Lee‐Iannotti, Joyce , Salat, David H. , Hamilton, Joanne M., Westbrook, Philip R., Mazeika, Gandis, Walsh, Christine M. , Tsuang, Debby W. , Berka, Chris , Shprecher, David , Mazeika, Gandis, Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A120-A121

10.1093/sleep/zsac079.265 Get It

Abstract Introduction The severity of REM sleep without atonia, a prodromal biomarker for synucleinopathy-related neurodegenerative disorders, is influenced by selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine retake inhibitor (SNRI) use. This study investigates whether SSRI/SNRIs similarly impacts the severity of Non-REM hypertonia (NRH), a biomarker independently associated with patients broadly characterized with presumed Parkinsonian-spectrum disorders (PSD). Methods In this multi-center study, the relationship between NRH and SSRI/SNRIs was evaluated in PSD patients [Lewy Body/Parkinson Disease Dementia (DLB/PDD=16), Parkinson Disease (PD=16), isolated REM sleep behavior disorder (iRBD=19), and progressive supranuclear palsy (PSP=12)], and non-PSD subjects [Alzheimer Disease (AD=22), mild cognitive impairment (MCI=35), and normal cognition (NC=61)]. Studies were conducted with the Sleep Profiler in all participants. NRH was auto-detected based on persistently elevated electromyographic (EMG) power relative to delta, theta, and sigma bands. Abnormal-NRH was based on a threshold of >5% of sleep time, and weight-averaged by sleep time, in the 75% of studies with two-nights of data. Statistical analyses included multiple logistic regression, Fisher Exact, and Mann-Whitney U tests. Results Across all 181 records, 38% had abnormal-NRH and 24% used SSRI/SNRIs (P<0.005). No differences were observed in the distributions of NRH for those with NRH-only vs. those with combined NRH and SSRI/SNRI use (n=45, 14.5+/-7.7% versus n=24, 18.6+/-11.6%, respectively; P=0.19). Abnormal-NRH was associated with the PSD versus non-PSD groups (P<0.0001, odds-ratio=14.0) and SSRI/SNRI use (P<0.05, odds-ratio=2.4), but not age and sex. Within the PSD and non-PSD groups, the frequency of abnormal-NRH was 75% vs. 19% (P<0.0001), and SSRI/SNRI use was 32% vs. 19% (P=0.07), respectively. The distributions of abnormal-NRH in the PSD and non-PSD subgroups ranged from PSP=92%, DLB/PDD=81%, PD=56% ,and RBD=74% versus MCI=26%, and NC=16%, AD=14%, respectively. By comparison, distributions of SSRI/SNRI use were DLB/PDD=50%, RBD=42%, PSP=33%, and PD=0% in the PSD subgroups, compared to MCI=34%, AD=23%, and NC=10% in the non-PSD subgroups. Conclusion Abnormal non-REM hypertonia exhibited a very strong association with Parkinsonian-spectrum disorder diagnoses (odds-ratio=14.0) and a relatively weaker association with selective serotonin reuptake inhibitor or serotonin-norepinephrine retake inhibitor use (odds-ratio=2.4), suggesting a finding that reflects an interactive, rather than causal inference. Support (If Any) NIA grants R44AG050326, R44AG054256, P30AG62677 and R34AG56639.
Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study
Kim, Soungmun, Jeong, Seogsong , Park, Sun Jae , Chang, Jooyoung , Choi, Seulggie , Cho, Yoosun , Ahn, Joseph , Lee, Gyeongsil , Son, Joung Sik , Ahn, Joseph C , Chang, Jooyoung , Park, Sang Min

Mayo Clinic

Journal of Clinical Medicine | May 19, 2022 | Volume: 11 | Issue: 10 | Pages: 2865

10.3390/jcm11102865 | PMID 35628991 Get It

(1) Background: The association between proton pump inhibitor (PPI) use and hepatocellular carcinoma (HCC) has been controversial, especially in the general population. We aimed to determine the impact of PPI on HCC risk in participants without liver cirrhosis or chronic hepatitis virus infection. (2) Methods: We assessed 406,057 participants from the Korean National Health Insurance Service database who underwent health screening from 2003 to 2006. We evaluated exposure to PPI before the index date using a standardized daily defined dose (DDD) system. The association of proton pump inhibitor use with the risk of HCC was evaluated using multivariable-adjusted Cox proportional hazards regression. (3) Results: Compared with non-users, PPI use was not associated with the HCC risk in low (<30 DDDs; aHR, 1.07; 95% CI, 0.91–1.27), intermediate (30 ≤ PPI < 60 DDDs; aHR, 0.96; 95% CI, 0.73–1.26), and high (≥60 DDDs; aHR, 0.86; 95% CI, 0.63–1.17) PPI groups in the final adjustment model. In addition, risks of cirrhosis-associated HCC and non-cirrhosis-associated HCC were not significantly associated with PPI use. The results remained consistent after excluding events that occurred within 1, 2, and 3 years to exclude pre-existing conditions that may be associated with the development of HCC. We also found no PPI-associated increase in HCC risk among the selected population, such as those with obesity, older age, and chronic liver diseases. (4) Conclusions: PPI use may not be associated with HCC risk regardless of the amount. We call for future studies conducted in other regions to generalize our findings.
Acquired peripheral nerve injuries associated with severe COVID-19
Franz, Colin K. , Murthy, Nikhil K. , Malik, George R. , D’Andrea, Dom, Wolfe, Alexis R. , Stearns, Melanie , Deshmukh, Swati , Tavee, Jinny , Sun, Fang , Swong, Kevin , Rydberg, Leslie , Wolfe, Lisa F. , Rogers, John A. , Franz, Colin K , Kwak, Jean Won , Farr, Ellen , Cotton, Ronald James , Walter, James McCauley , Coleman, John M.

Mayo Clinic

No container title available | May 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1623741/v1 Get It

Abstract We diagnosed 66 peripheral nerve injuries in 34 patients who survived severe coronavirus disease 2019 (COVID-19). We combine our latest data with published case series re-analyzed here (117 nerve injuries; 58 patients) to provide a comprehensive accounting of lesion sites. The most common are ulnar (25.1%), common fibular (15.8%), sciatic (13.1%), median (9.8%), brachial plexus (8.7%) and radial (8.2%) nerves at sites known to be vulnerable to mechanical loading. Protection of peripheral nerves should be prioritized in the care of COVID-19 patients. To this end, we report proof of concept data of a wearable, wireless pressure sensor to provide real time monitoring in the intensive care unit setting.
Impact of racial disparities and insurance status in patients with bone sarcomas in the USA
Hu, Xianglin , Houdek, Matthew T. , Huang, Wending, Sun, Zhengwang , Sun, Yangbai , Yan, Wangjun , Houdek, Matthew T , Huang, Wending , Sun, Zhengwang , Sun, Yangbai , Yan, Wangjun , Fujiwara, Tomohiro , Chen, Lingxiao

Mayo Clinic

Bone & Joint Research | May 12, 2022 | Volume: 11 | Issue: 5 | Pages: 278-291

10.1302/2046-3758.115.bjr-2021-0258.r2 | PMID 35549518 Get It

Aims Socioeconomic and racial disparities have been recognized as impacting the care of patients with cancer, however there are a lack of data examining the impact of these disparities on patients with bone sarcoma. The purpose of this study was to examine socioeconomic and racial disparities that impact the oncological outcomes of patients with bone sarcoma. Methods We reviewed 4,739 patients diagnosed with primary bone sarcomas from the Surveillance, Epidemiology and End Results (SEER) registry between 2007 and 2015. We examined the impact of race and insurance status associated with the presence of metastatic disease at diagnosis, treatment outcome, and overall survival (OS). Results Patients with Medicaid (odds ratio (OR) 1.41; 95% confidence interval (CI) 1.15 to 1.72) and uninsured patients (OR 1.90; 95% CI 1.26 to 2.86) had higher risks of metastatic disease at diagnosis compared to patients with health insurance. Compared to White patients, Black (OR 0.63, 95% CI 0.47 to 0.85) and Asian/Pacific Islander (OR 0.65, 95% CI 0.46 to 0.91) were less likely to undergo surgery. In addition, Black patients were less likely to receive chemotherapy (OR 0.67, 95% CI 0.49 to 0.91) compared to White patients. In patients with chondrosarcoma, those with Medicaid had worse OS compared to patients with insurance (hazard ratio (HR) 1.65, 95% CI 1.06 to 2.56). Conclusion In patients with a bone sarcoma, the cancer stage at diagnosis varied based on insurance status, and racial disparities were identified in treatment. Further studies are needed to identify modifiable factors which can mitigate socioeconomic and racial disparities found in patients with bone sarcomas. Cite this article: Bone Joint Res 2022;11(5):278–291.
Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis‐associated interstitial lung disease and idiopathic pulmonary fibrosis
Wang, Shaohua , Liu, Mengfei , Zhang, Jie , Wang, Faping , Zhang, Chujie , Roden, Anja C. , Ryu, Jay H. , Matteson, Eric L. , Tschumperlin, Daniel J. , Vassallo, Robert , Roden, Anja, Vassallo, Robert , Ryu, Jay H , Li, Xiujuan , Warrington, Kenneth J. , Sun, Jie

Mayo Clinic

The FASEB Journal | May 6, 2022 | Volume: 36 | Issue: 6 | Pages: No page available

10.1096/fj.202101436r | PMID 35522243 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) are two fibrotic interstitial lung diseases that share the usual interstitial pneumonia (UIP) injury pattern. Here, we report that RNA sequencing of lung biopsies from patients with RA‐ILD and IPF revealed shared and distinct disease‐causing pathways. Analysis of transcriptomic data identified a JAK2 related JAK/STAT signaling pathway gene signature that distinguishes RA‐UIP from idiopathic UIP. This was further confirmed by immunohistostaining, which identified JAK2 phosphorylation with two distinct forms of activation: a cytoplasmic form of JAK2 activation in most IPF cases (13/20) and a nuclear form of p‐JAK2 in RA‐UIP (5/5) and a minority of IPF (6/20) cases. Further immunohistostaining identified STAT5A&B as the downstream transcriptional activator for JAK2‐mediated canonical signal transduction and phosphorylation of Tyr41 on histone H3 (H3Y41ph) as the downstream epigenetic regulation site for JAK2‐mediated noncanonical signal transduction. Gene Set Enrichment Analysis (GSEA) of the RNA‐Seq data further supported this shared pathogenic mechanism for the two diseases with the enrichment of STAT5A&B target gene sets as well as the JAK2 regulated H3Y41ph target gene set. This regulatory role of JAK2 in the pathogenesis of pulmonary fibrosis was further demonstrated by the attenuation of bleomycin‐induced murine pulmonary fibrosis using a JAK2‐selective pharmacological inhibitor CEP33779. In vitro studies with normal and IPF derived lung fibroblasts revealed a central role for JAK2 as an essential intermediary molecule in TGF‐β‐mediated myofibroblast trans‐differentiation, proliferation, and extracellular matrix protein production. These observations support a crucial role for JAK2 as an intermediary molecule in fibrotic lung disease development.
Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer
Barfield, Richard , Huyghe, Jeroen R. , Lemire, Mathieu, Dong, Xinyuan, Su, Yu-Ru, Buchanan, Daniel D. , Figueiredo, Jane C. , Gallinger, Steven, Giannakis, Marios, Gsur, Andrea , Gunter, Marc J. , Harrison, Tabitha A. , Hopper, John L., Li, Christopher I., Newcomb, Polly A., Pai, Rish K. , Phipps, Amanda I., Qu, Conghui, Steinfelder, Robert S., Win, Aung Ko , Zaidi, Syed H., Peters, Ulrike , Brezina, Stefanie , Buchanan, Daniel D , Figueiredo, Jane C , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harrison, Tabitha A , Hudson, Thomas J , Moreno, Victor , Pai, R K , Pharoah, Paul D P , Sun, Wei , Win, Aung K , Campbell, Peter T , Peters, Ulrike , Hsu, Li , Barfield, Richard , Huyghe, Jeroen R , Lemire, Mathieu, Dong, Xinyuan, Su, Yu-Ru, Gallinger, Steven, Giannakis, Marios, Hopper, John L., Li, Christopher I., Newcomb, Polly A., Phipps, Amanda I., Qu, Conghui, Steinfelder, Robert S., Zaidi, Syed H.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 4, 2022 | Volume: 31 | Issue: 5 | Pages: 1068-1076

10.1158/1055-9965.epi-21-0724 | PMID 35247911 Get It

Abstract Background: Colorectal cancer has a strong epigenetic component that is accompanied by frequent DNA methylation (DNAm) alterations in addition to heritable genetic risk. It is of interest to understand the interrelationship of germline genetics, DNAm, and colorectal cancer risk. Methods: We performed a genome-wide methylation quantitative trait locus (meQTL) analysis in 1,355 people, assessing the pairwise associations between genetic variants and lymphocytes methylation data. In addition, we used penalized regression with cis-genetic variants ± 1 Mb of methylation to identify genome-wide heritable DNAm. We evaluated the association of genetically predicted methylation with colorectal cancer risk based on genome-wide association studies (GWAS) of over 125,000 cases and controls using the multivariate sMiST as well as univariately via examination of marginal association with colorectal cancer risk. Results: Of the 142 known colorectal cancer GWAS loci, 47 were identified as meQTLs. We identified four novel colorectal cancer–associated loci (NID2, ATXN10, KLHDC10, and CEP41) that reside over 1 Mb outside of known colorectal cancer loci and 10 secondary signals within 1 Mb of known loci. Conclusions: Leveraging information of DNAm regulation into genetic association of colorectal cancer risk reveals novel pathways in colorectal cancer tumorigenesis. Our summary statistics-based framework sMiST provides a powerful approach by combining information from the effect through methylation and residual direct effects of the meQTLs on disease risk. Further validation and functional follow-up of these novel pathways are needed. Impact: Using genotype, DNAm, and GWAS, we identified four new colorectal cancer risk loci. We studied the landscape of genetic regulation of DNAm via single-SNP and multi-SNP meQTL analyses.
Effect of olfactory bulb pathology on olfactory function in normal aging
Tremblay, Cécilia , Intorcia, Anthony J., Sue, Lucia I., Wilson, Jeffrey R. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Adler, Charles H. , Driver‐Dunckley, Erika

Mayo Clinic

Brain Pathology | April 29, 2022 | Volume: 32 | Issue: 5 | Pages: No page available

10.1111/bpa.13075 | PMID 35485279 Get It

AbstractDecline of olfactory function is frequently observed in aging and is an early symptom of neurodegenerative diseases. As the olfactory bulb (OB) is one of the first regions involved by pathology and may represent an early disease stage, we specifically aimed to evaluate the contribution of OB pathology to olfactory decline in cognitively normal aged individuals without parkinsonism or dementia. This clinicopathological study correlates OB tau, amyloid β (Aβ) and α‐synuclein (αSyn) pathology densities and whole brain pathology load to olfactory identification function as measured with the University of Pennsylvania Smell Identification Test (UPSIT) and clinical data measured proximate to death in a large autopsy study including 138 cases considered non‐demented controls during life. Tau pathology was frequently observed in the OB (95% of cases), while both Aβ (27% of cases) and αSyn (20% of cases) OB pathologies were less commonly observed. A weak correlation was only observed between OB tau and olfactory performance, but when controlled for age, neither OB tau, Aβ or αSyn significantly predict olfactory performance. Moreover, whole brain tau and αSyn pathology loads predicted olfactory performance; however, only αSyn pathology loads survived age correction. In conclusion, OB tau pathology is frequently observed in normally aging individuals and increases with age but does not appear to independently contribute to age‐related olfactory impairment suggesting that further involvement of the brain seems necessary to contribute to age‐related olfactory decline.
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal
Menkiszak, Janusz , McCuaig, Jeanna , Metcalfe, Kelly , Foulkes, William D. , Sun, Sophie , Karlan, Beth Y. , Eisen, Andrea , Olopade, Olufunmilayo I. , Senter, Leigha , Bordeleau, Louise , Sun, Ping , Narod, Steven A. , Kim, Raymond H. , Menkiszak, Janusz , Foulkes, William D , Karlan, Beth Y , Olopade, Olufunmilayo I , Couch, Fergus J. , Huzarski, Tomasz , Senter, Leigha , Singer, Christian F , Eng, Charis , Fruscio, Robert , Narod, Steven A , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Kotsopoulos, Joanne , Lubiński, Jan , Gronwald, Jacek , Neuhausen, Susan L. , Tung, Nadine , Couch, Fergus J. , Huzarski, Tomasz , Singer, Christian F. , Eng, Charis , Fruscio, Robert , Pal, Tuya

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 27, 2022 | Volume: 31 | Issue: 7 | Pages: 1351-1358

10.1158/1055-9965.epi-21-1196 | PMID 35477169 Get It

Abstract Background: The lack of consensus on whether bilateral oophorectomy impacts risk of developing breast cancer among BRCA1 mutation carriers might be attributed to various biases, specifically, cancer-induced testing bias due to inclusion of prevalent cases. We conducted two complementary matched case–control analyses to evaluate the association of oophorectomy and BRCA1 breast cancer. Methods: A research questionnaire was administered every two years to collect information on exposures and disease. In the first analysis, we limited the study to prevalent breast cancer cases (diagnosed prior to study entry; n = 2,962) who were matched to controls on year of birth and country of residence (n = 4,358). In the second approach, we limited to 330 incident cases (diagnosed in the follow-up period) and 1,548 matched controls. Conditional logistic regression was used to estimate the adjusted odds ratios (OR) and 95% confidence intervals (CI) of invasive breast cancer. Results: In the first approach, there was a significant inverse association between oophorectomy and the risk of developing breast cancer [OR = 0.43; 95% confidence interval (CI), 0.34–0.55; P &lt; 00001]. In the second approach, there was no association between oophorectomy and risk (OR = 1.21; 95% CI, 0.87–1.70; P = 0.26). Conclusions: The inclusion of women with a personal history of breast cancer prior to ascertainment likely impacts upon the association of oophorectomy and BRCA1 breast cancer risk. Impact: Oophorectomy is unlikely a determinant of breast cancer risk in BRCA1 mutation carriers but should be offered at age 35 to reduce the risk of ovarian and fallopian tube cancer.